Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very co...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Karger Publishers
2018-06-01
|
| Sraith: | Case Reports in Dermatology |
| Ábhair: | |
| Rochtain ar líne: | https://www.karger.com/Article/FullText/489661 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|